Reviews/Heart Failure Management/Finerenone reduces heart failure events in heart failure with mildly reduced or preserved ejection fraction
HFPEF · HFM-HFPEF-03 · v2
Borderline: within 4 points of the Established/Likely boundary, so a re-grade could land either side.
All of the directly relevant evidence here comes from one large randomised trial, FINEARTS-HF, in patients whose hearts pump at or above 40% of normal. In that trial finerenone lowered the total count of worsening heart-failure events (repeat hospitalisations and urgent visits combined) compared with placebo, and the benefit held steady no matter the pumping fraction, age, sex, weight, kidney status or other patient features examined [1][3][10]. A separate analysis of the same trial also showed fewer heart-failure hospitalisations when counted within a broader bundle of worsening-HF events [17]. The main caution is that every piece of evidence is a re-analysis of the same 6001 patients, so there is no second trial to confirm it. A further caution is that the headline number mixes hospitalisations together with urgent clinic visits rather than counting hospitalisations on their own, so the claim's exact wording runs slightly ahead of what was measured.
In FINEARTS-HF [1], the total number of worsening heart-failure events was 842 with finerenone versus 1024 with placebo (rate ratio 0.82; 95% CI 0.71 to 0.94; P=0.006), a reduction in the recurrent-event burden. The effect on total worsening HF events was consistent across the ejection-fraction spectrum [3] and across every prespecified subgroup examined, including age [10], sex [9], BMI [5], kidney risk [14] and frailty [15]. A secondary analysis [17] showed finerenone reduced an extended composite that includes HF hospitalisation (HR 0.85; 95% CI 0.78 to 0.92; P<0.001) and reduced outpatient oral diuretic intensification alone (HR 0.89; 95% CI 0.80 to 0.98; P=.02). All of this derives from a single trial of 6001 patients. The contested point: The division is between the measured endpoint and the claim's wording: the quantified 'total' reduction (rate ratio 0.82 [1]) is for worsening HF events defined as unplanned HF hospitalisation or urgent HF visit, and the corpus never isolates recurrent HF hospitalisations alone with their own rate ratio. Cardiovascular death was neutral (HR 0.93; 95% CI 0.78 to 1.11 [1]), so the composite is driven by the HF-event side, and the softer outpatient diuretic-intensification component [17] is open to ascertainment bias even though hospitalisations were centrally adjudicated.
All 22 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Heart Failure Management, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The entire relevant corpus is one trial (FINEARTS-HF, same 6001 patients re-analysed); there is no independent replication, so evidential independence is minimal.
The quantified 'total' reduction (RR 0.82) is for worsening HF events defined as unplanned HF hospitalisation OR urgent HF visit; the corpus never isolates recurrent HF hospitalisations alone with its own rate ratio, so the claim's wording ('hospitalisations') slightly overreaches the measured endpoint.
Where it remains uncertain. Every record is the same 6001-patient trial with no independent replication [1], and the measured endpoint bundles urgent visits with hospitalisations rather than isolating hospitalisations [1][17].
Aleatory
Several subgroup rate ratios have wide confidence intervals crossing 1, e.g. LVEF >=60% rate ratio 0.94 (0.70-1.25) [3] and age Q3 0.98 (0.76-1.26) [10], reflecting sampling variation within one trial.
Epistemic
All included evidence is FINEARTS-HF, the same 6001 patients [1]; a second trial could reduce this uncertainty but does not exist in the corpus.
Inferential
The reported total-burden reduction is for worsening HF events (hospitalisation or urgent visit) [1], so inferring a hospitalisation-specific burden reduction requires a step the quantified endpoint does not make explicit.
The load-bearing papers from a corpus of 22, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Direct quantification: significant reduction in total (recurrent) worsening HF events, the burden measure the claim concerns.
“The total number of worsening heart failure events was 842 in the finerenone group and 1024 in the placebo group (rate ratio, 0.82; 95% CI, 0.71 to 0.94; P = 0.006).”
Panel auditInternal validity: high · scope of inference: Patients with HF and LVEF >=40% on usual therapy; total worsening HF event burden and CV death.Key limitations: worsening HF events include urgent visits not only hospitalisations · component not formally alpha-protected against composite
Shows the total HF-event reduction holds across the LVEF range, strengthening applicability to the HFmrEF/HFpEF population named in the claim.
“There was a similar consistent effect of finerenone on reducing the total number of worsening HF events (continuous P interaction=0.26).”
Panel auditInternal validity: high · scope of inference: Whether finerenone's HF-event and composite benefit varies by LVEF in HFmrEF/HFpEF.Key limitations: subgroup consistency analysis · no isolated CI for HF-event effect in this abstract
Confirms reduction of HF hospitalisation within the broader worsening-HF composite, corroborating the hospitalisation component of the claim.
“Finerenone reduced outpatient oral diuretic intensification alone (hazard ratio [HR], 0.89 [95% CI, 0.80-0.98]; P = .02) and in an extended composite outcome that further included cardiovascular death, HF hospitalization, and urgent HF visit (HR, 0.85 [95% CI, 0.78-0.92]; P < .001).”
Panel auditInternal validity: high · scope of inference: Full spectrum of worsening HF events (hospitalisation, urgent visit, outpatient diuretic intensification) with finerenone in HFmrEF/HFpEF.Key limitations: reported effect size is for an extended composite, not HF hospitalisation alone · outpatient diuretic intensification not centrally adjudicated as part of primary outcome
3 of 22 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
A single large positive RCT directly supports the claim, but reliance on one trial and the endpoint bundling urgent visits with hospitalisations hold it below Established.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Independent replication outside FINEARTS-HF. Every included record is the same 6001-patient trial [1], so the finding has no external confirmation. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A second adequately powered randomised trial of finerenone in HFmrEF/HFpEF, or a participant-level meta-analysis once a comparable trial exists, reporting recurrent HF-event burden.
Open question: Does finerenone reduce recurrent HF hospitalisations when counted separately from urgent HF visits? Why it is still open: The corpus reports only the bundled worsening-HF-event rate ratio [1] and an extended composite [17], never hospitalisations in isolation.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19